SCM
SABS icon

Stonepine Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Stonepine Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$192K Buy
+50,000
New +$199K 0.08% 72

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Stonepine Capital Management's SABS Position: Q1 2026 in Review

Stonepine Capital Management opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 50,000 shares worth $192K. The stake represents 0.08% of the portfolio and ranks #72 among its holdings.

76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Stonepine Capital Management held 50,000 shares of SAB Biotherapeutics worth $192K as of Q1 2026.
  • SAB Biotherapeutics was a new Stonepine Capital Management position in Q1 2026.
  • SAB Biotherapeutics made up 0.08% of Stonepine Capital Management's portfolio in Q1 2026, its #72 holding.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.